Cantourage (HIGH1.DE) Holds Steady Amid Market Volatility
Cantourage, the German medical‑cannabis supplier listed on Xetra, recorded a stagnant 0 % change over the 24‑hour period ending 01:08 AM Central Europe on Thursday 22nd. The stock trades at roughly EUR 5.04, with a market capitalisation of EUR 59 million and a circulating supply of 11.8 million shares. In the last 24 hours, only EUR 22.8 k worth of shares changed hands, reflecting a shallow liquidity profile.
Technical Landscape
The current price sits EUR 5.04, just 0.23 % below the simple moving average (SMA) calculated over the last 200 days (EUR 5.27). Historically, Cantourage’s 52‑week high reached EUR 6.86 on 29 May 2026, while the low dipped to EUR 2.32 on 26 November 2025. The stock’s performance has slipped 13.44 % since the end of last month, signalling a downward trend that has yet to be corrected.
Peer Comparison
The surrounding cohort of German‑listed cannabis and medical‑goods firms demonstrates a mixed bag of outcomes:
| Stock | % Change (24 h) | Current Price | Market Cap (m EUR) | P/E Ratio |
|---|---|---|---|---|
| Pwo (PWO.DE) | 0 % | 21.2 | 67.5 | 24.41 |
| Net Digital (VRL.DE) | –0.33 % | 30.2 | 65.5 | – |
| Albis Leasing (ALG.DE) | 0 % | 3.28 | 69.5 | 14.99 |
| Wegrow (ZN2.DE) | +2.27 % | 3.6 | 70 | – |
| Ad Pepper Media (APM.DE) | +3.73 % | 2.8 | 66.7 | 95.14 |
While the group is broadly flat, a few peers show modest gains, hinting at a sector‑wide resilience that Cantourage has failed to capture. Notably, Ad Pepper Media’s staggering P/E of 95.14 underscores the inflated valuations some investors still attach to cannabis‑related stocks, a bubble that Cantourage’s fundamentals do not justify.
Fundamental Concerns
Cantourage’s business model relies on the supply of medicinal cannabis products, including dronabinol, cannabidiol, and extracts. Yet, the company has yet to demonstrate a scalable revenue engine that can weather regulatory shifts or market competition. Its modest trading volume—only a few thousand euros in the last day—suggests that market participants are skeptical about the firm’s growth prospects.
Furthermore, the flat 0 % daily movement may mask a broader lack of investor confidence. In an environment where peers are either marginally rising or declining, Cantourage’s inertia could be interpreted as a lack of strategic direction rather than a healthy consolidation.
Outlook
Given the current price below the 200‑day SMA, a downward bias, and thin liquidity, investors should treat Cantourage with caution. Unless the company delivers a clear turnaround strategy—perhaps by diversifying its product portfolio, securing new regulatory approvals, or forming strategic partnerships—its share price may continue to drift lower, potentially eroding shareholder value.
In the short term, Cantourage appears to be a “waiting‑for‑something” stock. For those willing to gamble on a medical‑cannabis provider that has yet to prove its mettle, the price is affordable. However, the evidence points to a cautious approach: the market has already signalled its ambivalence, and the stock’s performance remains stagnant amid a sector that is otherwise showing modest gains.
